Targeting neuroinflammation to enhance recovery after brain injury

Traumatic brain injury (TBI) continues to be a major global cause of morbidity and mortality, with neuroinflammation recognized as a central mechanism influencing both acute and long-term outcomes. Following the initial insult, activation of glial cells, cytokine release, and blood-brain barrier disruption drive a cascade of secondary injury. While these inflammatory processes contribute to debris clearance and neurorepair, excessive or prolonged activation leads to neuronal death and chronic neurodegeneration. Recent international research has focused on modulating these pathways to enhance recovery. In the United States and Germany, trials using stem cell derived exosomes and anti-cytokine biologics have shown neuroprotective potential. In China, novel compounds such as 3-monothiopomalidomide have demonstrated efficacy in reducing microglial activation and improving behavioral outcomes in experimental TBI. Integrating these pharmacological, cellular, and imaging innovations into clinical care could transform TBI management. This letter underscores the need for global collaboration, transparent data use, and biomarker-driven neuroinflammatory modulation to optimize adult brain injury recovery.